Abstract
Meeting abstracts A previous clinical trial carried out by our group in which high numbers of haploidentical donor lymphoid cells containing CD3+ cells (1 - 2 x 108 CD3+ cells/kg) were infused into recipients with refractory hematological malignancy found that 14/27 patients gave a response, 9 or
Highlights
Convenient online submission Thorough peer review No space constraints or color figure charges Immediate publication on acceptance Inclusion in PubMed, CAS, Scopus and Google Scholar Research which is freely available for redistribution
A previous clinical trial carried out by our group in which high numbers of haploidentical donor lymphoid cells containing CD3+ cells (1 - 2 x 108 CD3+ cells/kg) were infused into recipients with refractory hematological malignancy found that 14/27 patients gave a response, 9 or which were major
No persisting donor cells could be detected at 2 weeks following infusion
Summary
Fast et al Journal for ImmunoTherapy of Cancer 2013, 1(Suppl 1):P7 http://www.immunotherapyofcancer.org/content/1/S1/P7 Use of cellular immunotherapy for treatment of refractory acute myeloid leukemia Loren Fast*, John Reagan, Peter Quesenberry From Society for Immunotherapy of Cancer 28th Annual Meeting National Harbor, MD, USA. A previous clinical trial carried out by our group in which high numbers of haploidentical donor lymphoid cells containing CD3+ cells (1 - 2 x 108 CD3+ cells/kg) were infused into recipients with refractory hematological malignancy found that 14/27 patients gave a response, 9 or which were major.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
